Search

Displaying results 9211 - 9220 of 10000 in total
  1. Drug

    Elsibucol

    go.drugbank.com/drugs/DB05840
    Experimental

    -1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in

  2. Drug

    EU204

    go.drugbank.com/drugs/DB17438
    Investigational

    EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.

  3. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  4. Drug

    Aspartyl-alanyl-diketopiperazine

    go.drugbank.com/drugs/DB14940
    Investigational

    Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).

  5. Drug

    NPS-2143

    go.drugbank.com/drugs/DB05695
    Experimental

  6. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

  7. Drug

    Phthalylsulfathiazole

    go.drugbank.com/drugs/DB13248
    Approved

    It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006].

  8. Drug

    Fradafiban

    go.drugbank.com/drugs/DB06472
    Experimental

  9. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers.

  10. Drug

    Refametinib

    go.drugbank.com/drugs/DB06309
    Investigational